Project Grant R43DK122874

This Project Grant award from the National Center for Advancing Translational Sciences (CFDA 93.350) provides $350,000 to Adiutrix Therapeutics LLC to develop a novel anti-fibrotic compound platform to identify and develop first-in-class therapeutics targeting collagen prolyl-4 hydroxylase (C-P4H) activity. The goal is to treat tissue remodeling and fibrosis in underserved diseases such as idiopathic pulmonary fibrosis (IPF), scleroderma skin fibrosis, kidney fibrosis, and intestinal fibrosis...

This Project Grant award of $389,754 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to assess the therapeutic potential of a peptide derived from collagen XVIII for treating lung fibrosis associated with systemic sclerosis (scleroderma). The project aims to evaluate the anti-fibrotic effects of this peptide in a murine model of lung fibrosis, as well as identify the minimal effective dose, optimal...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), is funding the development of a novel drug candidate to treat idiopathic pulmonary fibrosis (IPF). The award of $356,250 will support a two-phase project by Vasarya Therapeutics, Inc. to perform affinity maturation and liability assessment on a tool compound called VSR-H5, which has demonstrated the ability to selectively target and inhibit...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), provides $464,121 to The Medical University of South Carolina to develop peptides derived from collagen XVIII for the treatment of pulmonary fibrosis. The project aims to simultaneously test the identified peptides in preclinical models of fibrosis, identify a lead candidate, characterize its efficacy, conduct dose escalation...

The National Heart, Lung, and Blood Institute (NHLBI) awarded Novomedix LLC a $306,872 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to develop novel oral small molecule therapeutics for the treatment of progressive pulmonary fibrosis, including idiopathic pulmonary fibrosis (IPF). The goal is to create a safer and more effective therapy compared to the currently approved drugs, which only slow disease progression and have significant side effects. Novomedix will...

This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $1,182,632 to Eydis Bio, Inc. to advance the development of their small molecule TAK1 inhibitor HS-276 as a potential treatment for systemic sclerosis-associated interstitial lung disease (SSc-ILD). The key research activities funded under this 2-year award include in vivo pharmacodynamic studies of HS-276 in murine lung...

The project grant award of $301,373 was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to S1P Therapeutics Inc. (doing business as Flux Therapeutics LLC). The purpose of the award is to develop SPNS2 inhibitors as potential therapies for renal fibrosis, a serious complication of chronic kidney disease. Specifically, the project aims to identify a lead SPNS2...

This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $2,323,927 to The Regents of the University of California, San Francisco (UCSF) to conduct research on the role of inflammatory fibroblasts in the development of pulmonary fibrosis. The key objectives of this 4-year research project are to: 1) characterize the emergence, persistence, and fate of inflammatory fibroblasts in mouse...

The National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health, has awarded a $160,500 Project Grant to Childrens Hospital Medical Center in Cincinnati, Ohio. The grant, designated as CFDA 93.350, will fund the establishment of a novel zebrafish model to study the pathogenesis of Progressive Familial Intrahepatic Cholestasis Type I (PFIC1), a rare genetic liver disease caused by mutations in the ATP8B1 gene. The key objectives are to: 1)...

The University of Kentucky Research Foundation received a $698,070 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to conduct research on targeting lung fibrosis using epigenetic therapy. The 4-year project, which commenced on August 15, 2024, aims to examine whether the FDA-approved EZH2 inhibitor Tazemetostat can prevent or reverse aberrant epithelial cell fate and pro-fibrotic signaling in organotypic cell cultures and in...